Evaluation of the relationship between various histopathological types of primary malignant thyroid carcinoma and blood groups
Abstract
Background: The ABO and Rh system have a great associationto different kind of malignancy as mentioned in the literature.
The data about prevalence of blood group with thyroid
malignancies were limited in the literature; we aimed to record
the relationship of different ABO and Rh blood groups with
different malignant thyroid tumors.
Methodology: the demographics, ABO blood group, Rh factor,
histopathological type of malignant thyroid tumors were
recorded for each patient with malignant thyroid tumor (MTT);
then we evaluated the association between different blood group
types with different histopathological pattern.
Results: the commonest type of malignant thyroid carcinoma
was Papillary thyroid carcinoma (PTC) [n=46, (92%)], while all
other types were uncommon, they were follicular thyroid
carcinoma [(n=1) 2%], medullary thyroid carcinoma [(n=1) 2%],
Hürthle cell carcinoma [(n=1) 2%] and anaplastic thyroid
carcinoma [(n=1) 2%]., the blood group A with Rh positive was
the most frequent [n= 17, (34%)], , the O+ve was [n=15 (30%)],
B+ve [n=10 (20%)], while AB-ve [n=3 (6%)] while a small
number was Rhesus negative. The A+ve blood group was the
commonest blood group in PTC patients (34.8%), followed by
O+ve (30.4%).
Conclusion: Blood group A+ve is the most frequently reported
among cases of papillary thyroid carcinoma, which is the most
common MTT.
References
Wartofsky L, Van Nostrand D. Thyroid cancer: a comprehensive
guide to clinical management: Springer; 2006.
Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for
thyroid carcinoma: A population‐based study of 15,698 cases from the
Surveillance, Epidemiology and End Results (SEER) Program 1973–1991.
Cancer: Interdisciplinary International Journal of the American Cancer Society.
;79(3):564-73.
Yang H, Yan J. A systematic review of prognosis of ABO blood
group and rhesus factor on outcomes in patients with bladder cancer. Medicine.
;101(39):e30893.
Wang J, García-Bailo B, Nielsen DE, El-Sohemy A. ABO
genotype,‘blood-type’diet and cardiometabolic risk factors. PloS one.
;9(1):e84749.
Liumbruno GM, Franchini M. Hemostasis, cancer, and ABO blood
group: the most recent evidence of association. Journal of thrombosis and
thrombolysis. 2014;38:160-6.
Kim D-S, Scherer PE. Obesity, diabetes, and increased cancer
progression. Diabetes & metabolism journal. 2021;45(6):799-812.
Hovinga ICK, Koopmans M, de Heer E, Bruijn JA, Bajema IM.
Change in blood group in systemic lupus erythematosus. The Lancet.
;369(9557):186-7.
Edition S, Edge S, Byrd D. AJCC cancer staging manual. AJCC
cancer staging manual. 2017.
Lang TA, Secic M. How to report statistics in medicine: annotated
guidelines for authors, editors, and reviewers: ACP Press; 2006.
Habibzadeh F. Common statistical mistakes in manuscripts submitted
to biomedical journals. European Science Editing. 2013;39(4):92-4.
Habibzadeh F. Statistical data editing in scientific articles. Journal of
Korean medical science. 2017;32(7):1072-6.
Karhu D, Vanzieleghem M. Significance of digits in scientific
research. AMWA J. 2013;28(2):58-60.
Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain K,
Bigos S, et al. The impact of age and gender on papillary thyroid cancer survival.
The Journal of Clinical Endocrinology & Metabolism. 2012;97(6):E878-E87.
Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity.
Future Oncology. 2010;6(11):1771-9.
Yager J, Leihr J. Molecular mechanisms of estrogen carcinogenesis.
Annual review of pharmacology and toxicology. 1996;36(1):203-32.
Lee M, Chen G, Vlantis A, Tse G, Leung B, Van Hasselt C. Induction
of thyroid papillary carcinoma cell proliferation by estrogen is associated with an
altered expression of Bcl-xL. The Cancer Journal. 2005;11(2):113-21.
Zeng Q, Chen G, Vlantis A, Van Hasselt C. Oestrogen mediates the
growth of human thyroid carcinoma cells via an oestrogen receptor–ERK
pathway. Cell Proliferation. 2007;40(6):921-35.
Ortega J, Sala C, Flor B, Lledo S. Efficacy and cost-effectiveness of
the UltraCision® harmonic scalpel in thyroid surgery: an analysis of 200 cases in
a randomized trial. Journal of Laparoendoscopic & Advanced Surgical
Techniques. 2004;14(1):9-12.
Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated
thyroid cancer in the United States, 1988–2005. Cancer: Interdisciplinary
International Journal of the American Cancer Society. 2009;115(16):3801-7.
Moysich KB, Menezes RJ, Michalek AM. Chernobyl-related ionising
radiation exposure and cancer risk: an epidemiological review. The Lancet
Oncology. 2002;3(5):269-79.
Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch
V, et al. Risk of thyroid cancer after exposure to 131 I in childhood. Journal of
the National Cancer Institute. 2005;97(10):724-32.
Parad MT, Fararouei M, Mirahmadizadeh AR, Afrashteh S. Thyroid
cancer and its associated factors: A population‐based case‐control study.
International Journal of Cancer. 2021;149(3):514-21.
LeClair K, Bell KJ, Furuya-Kanamori L, Doi SA, Francis DO, Davies
L. Evaluation of gender inequity in thyroid cancer diagnosis: differences by sex
in US thyroid cancer incidence compared with a meta-analysis of subclinical
thyroid cancer rates at autopsy. JAMA Internal Medicine. 2021;181(10):1351-8.
Franceschi S, Boyle P, Maisonneuve P, La Vecchia C, Burt AD, Kerr
DJ, et al. The epidemiology of thyroid carcinoma. Critical reviews in
oncogenesis. 1993;4(1):25-52.
Davies L, Welch HG. Increasing incidence of thyroid cancer in the
United States, 1973-2002. Jama. 2006;295(18):2164-7.
Zhu C, Zheng T, Kilfoy BA, Han X, Ma S, Ba Y, et al. A birth cohort
analysis of the incidence of papillary thyroid cancer in the United States, 1973–
Thyroid. 2009;19(10):1061-6.
Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S,
et al. SEER Cancer Statistics Review, 1975–2013. Bethesda, MD: National
Cancer Institute; 2016. 2016.
Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. The
Lancet. 2016;388(10061):2783-95.
Bonnefond S, Davies TF. Thyroid cancer—risks and causes. JournalThyroid Cancer—Risks and Causes. 2014.
Reid ME, Mohandas N, editors. Red blood cell blood group antigens:
structure and function. Seminars in hematology; 2004: Elsevier.
Tam AA, Özdemir D, Fakı S, Bilginer MC, Ersoy R, Çakır B. ABO
blood groups, Rh factor, and thyroid cancer risk: to ‘B’or not to ‘B’. Endocrine
research. 2020;45(2):137-46.
Franchini M, Liumbruno GM. ABO blood group: old dogma, new
perspectives. Clinical Chemistry and Laboratory Medicine (CCLM).
;51(8):1545-53.
Edgren G, Hjalgrim H, Rostgaard K, Norda R, Wikman A, Melbye M,
et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a
cohort study. American journal of epidemiology. 2010;172(11):1280-5.
Hakomori S-i. Antigen structure and genetic basis of histo-blood
groups A, B and O: their changes associated with human cancer. Biochimica et
Biophysica Acta (BBA)-General Subjects. 1999;1473(1):247-66.
Zhang B-L, He N, Huang Y-B, Song F-J, Chen K-X. ABO blood
groups and risk of cancer: a systematic review and meta-analysis. Asian Pacific
Journal of Cancer Prevention. 2014;15(11):4643-50.
Coussens LM, Werb Z. Inflammation and cancer. Nature.
;420(6917):860-7.
Li C, Xu F, Huang Q, Han D, Zheng S, Wu W, et al. Nomograms for
differentiated thyroid carcinoma patients based on the eighth AJCC staging and
competing risks model. JNCI Cancer Spectrum. 2021;5(3):pkab038.
Kakudo K, Tang W, Ito Y, Mori I, Nakamura Y, Miyauchi A.
Papillary carcinoma of the thyroid in Japan: subclassification of common type
and identification of low risk group. Journal of clinical pathology.
;57(10):1041-6
Downloads
Published
Issue
Section
License
Copyright (c) 2023 University of Thi-Qar Journal Of Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
